Related Experiment Videos
Small non-cleaved cell lymphoma in adults
1Div. of Clinical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
American Journal of Hematology
|September 1, 1991
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology·2010
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
Annals of oncology : official journal of the European Society for Medical Oncology·2007
Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology·2003
Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning.
Health psychology : official journal of the Division of Health Psychology, American Psychological Association·2001
Burnout: caring for the caregivers.
The oncologist·2000
POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management.
American journal of hematology·2026
High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.
American journal of hematology·2026
Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.
American journal of hematology·2026
Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.
American journal of hematology·2026
Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.
Case reports in dermatological medicine·2026
Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.
Frontiers in endocrinology·2026
Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.
Kidney diseases (Basel, Switzerland)·2026
Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.
Frontiers in cell and developmental biology·2026